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Summary 
Background and Purpose: Lacunar stroke accounts for approximately 25% of 
ischemic stroke but optimal antiplatelet regimen to prevent stroke recurrence remains 
unclear. We aimed to evaluate the efficacy of antiplatelet agents in secondary stroke 
prevention following a lacunar stroke.   
Methods: We searched MEDLINE, EMBASE and the Cochrane library for RCTs 
that reported risk of recurrent stroke or death with antiplatelet therapy in patients with 
lacunar stroke. We used random effects meta-analysis and evaluated heterogeneity 
with I2.  
Results: We included 17 trials with 42,234 participants (mean age 64.4 years, 65% 
male) and follow up ranging from 4 weeks to 3.5 years. Compared to placebo, any 
single antiplatelet agent was associated with a significant reduction in recurrence of 
any stroke (RR 0.77, 0.62-0.97, 2 studies) and ischemic stroke (RR 0.48,0.30-0.78, 2 
studies), but not for the composite outcome of any stroke, myocardial infarction or 
death (RR 0.89,0.75-1.05, 2 studies). When other antiplatelet agents (ticlodipine, 
cilostazol, and dipyridamole) were compared to aspirin, there was no consistent 
reduction in stroke recurrence (RR 0.91, 0.75-1.10, 3 studies).  Dual antiplatelet 
therapy did not confer clear benefit over monotherapy (any stroke RR 0.83, 0.68-1.00, 
3 studies; ischemic stroke RR 0.80, 0.62-1.02, 3 studies; composite outcome RR 0.90, 
0.80-1.02, 3 studies).   
Conclusions: Our results suggest that any of the single antiplatelet agents compared 
to placebo in the included trials is adequate for secondary stroke prevention after 
lacunar stroke. Dual antiplatelet therapy should not be used for long-term stroke 
prevention in this stroke subtype.   
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Introduction  
Lacunar stroke or small vessel ischemic stroke represents about 25% of all ischemic 
strokes [1]. Whilst the functional prognosis of single episode of lacunar stroke is 
generally good, recurrence is not uncommon [2,3]. The underlying etiology is 
believed to be cerebral small vessel disease (CSVD) in the form of arteriolosclerosis 
of deep penetrating arteries.  This mechanism is thought to be the most frequent cause 
of vascular cognitive impairment [4]. Therefore, preventing progression of CSVD is 
extremely important. Current therapeutic options are however limited and the 
comparative efficacy of available antiplatelet agents remains uncertain.  
 
Until recently, all of the evidence supporting the use of antiplatelet agents as 
secondary prevention following lacunar stroke came from subgroup analysis from 
randomized controlled trials (RCTs) designed to assess the efficacy of these agents in 
all ischemic stroke subtypes.  However, these subgroups generally have small sample 
sizes.  The Secondary Prevention of Small Subcortical Strokes (SPS3) trial was the 
first to address the question at hand in a RCT with a large (n=3020) well-defined 
population of magnetic resonance imaging (MRI) confirmed lacunar stroke, 
comparing aspirin monotherapy to dual antiplatelet therapy (DAPT) with aspirin and 
clopidogrel. This trial was however terminated early due to lack of efficacy and 
increased mortality amongst participants randomized to dual antiplatelet therapy [3]. 
In view of the paucity of data, differing vascular pathology underlying lacunar stroke, 
and the recent SPS3 trial results, the utility of antiplatelet monotherapy has been 
questioned in this population [5]. 
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The primary aim of this study is to evaluate the evidence for antiplatelet therapy as 
secondary stroke prevention in patients with lacunar stroke. We performed a 
systematic review and pooled meta-analysis of RCTs. 
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Methods 
Eligibility criteria 
We included RCTs that evaluated the use of antiplatelet therapy as secondary 
prevention following acute stroke.  Among these trials, only those which reported 
outcomes separate for lacunar stroke were included. For certain trials additional data 
were obtained via personal correspondence from the authors.   
 
Outcomes 
Primary outcome of interest was any stroke recurrence (ischemic or hemorrhagic). 
Secondary outcomes of interest were: a) recurrent ischemic stroke and b) composite 
of any stroke, myocardial infarction and death. We accepted composite outcomes as 
specified by trial investigators so long as strokes and deaths were captured in the 
composite end point. 
 
Search strategy 
MEDLINE and EMBASE searches with no date limitations or language restrictions 
were conducted in December 2013 using the broad search terms as shown in 
Supplementary Data I. Furthermore, we reviewed the bibliography of included trials, 
Cochrane Reviews and the most recent review by the antithrombotic trialist 
collaboration for additional studies.  
 
Study selection and data extraction 
Two reviewers (CSK and AS) considered all titles and abstracts retrieved from the 
search for potential eligibility. Where there was disagreement, study inclusion or 
exclusion was agreed upon by consensus with the other authors.  Two reviewers (CSK 
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and HCC) independently extracted information on study design, participant 
characteristics, types of interventions, outcomes, results and risk of bias onto a 
spreadsheet.  The two extractions were compared and differences were resolved by 
consensus.  Where there was uncertainty journal authors were contacted for 
clarification. 
 
Assessment of risk of bias 
Two reviewers (CSK and HCC) independently assessed the individual studies’ risks 
of bias in accordance with the recommendations of the Cochrane Collaboration which 
included baseline differences, blinding, lost to follow up, exposure and outcome 
ascertainment and conflicts of interest.  We planned to assess publication bias using 
funnel plots if there were >10 studies included in the meta-analysis and there was no 
significant statistical heterogeneity [6]. 
 
Statistical analysis 
Fixed effects meta-analysis of dichotomous events was performed using RevMan 5.3 
(Nordic Cochrane Centre, København, Denmark) in order to estimate pooled risk 
ratios (RRs). Statistical heterogeneity was assessed using I2 statistic, with values of 
30-60% representing a moderate level of heterogeneity [7]. We performed secondary 
analysis considering only ischemic stroke as the outcome. Annual event rates per 100 
patient years of follow-up were estimated by adjusting the studies event rate 
according to the trial’s mean follow-up duration.  
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Results 
We included a total of 17 randomized trials that included 42,234 participants with 
lacunar stroke treated with antiplatelet therapy (mono or dual) or placebo [3,8-23]. 
We did not include 4 trials (IST [11], PERFORM [21], S-ACCESS [17] and TRA 2P-
TIMI50 [22]) in our pooled analysis. IST’s composite outcome of death and 
dependency did not match our criteria and TRA 2P–TIMI50 did not provide number 
of events. Novel less established agents were excluded from the analysis in an attempt 
to reduce the level heterogeneity between the different agents’ mechanisms of action, 
but their results are reported separately (Saprogelate (S-ACCESS) [17] and 
Terutroban (PERFORM) [21] trials).  The process of study selection is shown in 
Supplementary Figure I.  Table 1 shows the summary characteristics of the study 
populations of included studies. Of these 14 were double-blind randomized trials. The 
mean age was 64 years and 65% of participants were male across 16 studies; one 
study (IST) reported 61% of participants >70 years of age and one study (CSPS2) 
[18] did not report the number of male and female participants.  All the studies 
included participants with suspected ischemic stroke or transient ischemic attack and 
neuroimaging was performed to confirm diagnosis in all but one study (CATS) [9], 
which relied on neurological evaluation for diagnosis.  Only six of the studies 
formally defined lacunar stroke using criteria such as the TOAST Criteria, modified 
Fisher criteria or other pre-defined criteria and only one used MRI to verify the 
diagnosis of lacunar stroke [3]. 
 
Supplementary Table I shows the quality assessment of the studies included.  
Sequence generation of randomization was described in 10 studies and allocation 
concealment was described in 13 studies.  14 trials were double blind trials and some 
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means to assess treatment exposure or compliance was considered in 8 trials.  All but 
one study had some form of outcome ascertainment and 4 studies had unclear 
participant lost to follow-up. 
 
The treatments received, crude events rate, outcomes and results are shown in 
Supplementary Table II. The follow up of the studies ranged from 4 weeks to 3.5 
years. 
 
Any single antiplatelet agent vs. placebo 
Overall, patients on antiplatelet monotherapy had significantly lower rates of any 
stroke as compared to placebo (RR 0.77, 0.62-0.97, 2 trials, CATS [9], ESPS-2 [19]).  
There was a significant reduction in ischemic stroke (RR 0.48, 0.30-0.78, 2 trials, 
AICLA [8], Matsumoto [14]) but not in the composite outcome (RR 0.89, 0.75-1.05, 
2 trials CAST [10], ESPS-2 [19]).  Results of these analyses are shown in Figure 1A-
C. 
 
Cilostazol, ticlopidine, dipyridamole, terutobran, sarpogrelate vs. aspirin alone 
Overall, the meta-analysis shows no significant advantage of other single agents 
above aspirin alone.  These analyses are shown in Figure 2 A-B. Two trials, 
PERFORM [21] and S-ACCESS [17], evaluating terutroban and sarpogrelate also 
found no significant benefit above aspirin alone (terutroban HR 0.90,0.62-1.31, 
sarpogrelate HR 1.31,0.84-2.04). 
 
Dual antiplatelet therapy (DAPT) vs. aspirin alone 
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The results of DAPT versus aspirin are shown in Figure 3.  Overall, DAPT may 
possibly have a modest advantage over aspirin but this is driven mainly by the 
aspirin/dipyridamole data from ESPS-2 [19]. The pooled risk ratio for any stroke, 
ischemic stroke and the composite outcome were RR 0.83, 0.68-1.00, RR 0.80,0.62-
1.02 and RR 0.95,0.85-1.07, respectively. 
 
Dipyridamole/aspirin, clopidogrel/aspirin and ticlopidine vs. clopidogrel alone 
We observed no significant advantage of DAPT vs. clopidogrel, or ticlopidine vs. 
clopidogrel.  For this analysis aspirin/dipyridamole did not appear to be superior to 
clopidogrel alone.  Results are shown in Figure 4. Finally, DAPT using vorapaxar in 
addition to aspirin or clopidogrel use showed no significant benefit on vascular 
endpoints (HR 0.99,0.75-1.31) [22]. 
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Discussion  
The current American Heart Association guidelines [24] state that four antiplatelet 
regimens (aspirin, clopidogrel, ticlopidine or the combination of dipyridamole and 
aspirin) have been shown to reduce the risk of ischemic stroke after stroke or TIA. 
The guidelines further suggest that several factors should be considered such as 
patient comorbidities, side effects and costs when choosing an agent at an individual 
level.  Suitably, our findings suggest that antiplatelet monotherapy (i.e. aspirin, 
dipyridamole, clopidogrel, cilostazol, ticlopidine) should be recommended as 
secondary prevention of stroke among patients with lacunar stroke.  Aspirin appears 
to be as good as any other antiplatelet agents, and is likely the appropriate first line in 
most because it is less expensive, and generally well tolerated, which may increase 
long-term adherence to therapy [24].  Cilostazol showed a non-significant trend in 
reducing strokes when compared with aspirin, however further larger studies are 
needed to validate these findings and ensure generalizability to non-East Asian 
populations. 
 Unfortunately, in view of the limited number of studies which evaluate the role of 
DAPT we are unable to separate out individual agents and maintain a meaningful 
pooled analysis.  Accordingly, we identified substantial heterogeneity in the effects of 
DAPT, which vary depending on the choice of the combination and the comparator 
drugs. Only one trial shows DAPT to be favorable (ESPS-2), but the superiority of 
dipyridamole and aspirin was not replicated when clopidogrel was used as the control 
rather than aspirin. Moreover, long-term DAPT with clopidogrel/aspirin led to 
significantly higher rates of major bleeding in MATCH, and all-cause mortality in 
SPS3. Therefore, current evidence does not justify the use of long-term DAPT in 
patient with lacunar stroke.   
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Our results are in line with those of the SPS3 trial regarding the lack of benefit from 
clopidogrel and aspirin therapy in lacunar stroke patients.  We however did not notice 
any significant increase in our composite outcome of any stroke, myocardial 
infarction and death.  Limited by the available published data, we were unable to 
consider mortality rates in isolation, however long-term dual antiplatelet therapy 
(mean 3.4 years) led to increased all-cause mortality (HR 1.52, 1.14-2.04, p=0.004) in 
comparison to monotherapy with aspirin within SPS3 [3].  
 
Our study has limitations.  There were a limited number of trials and there was 
insufficient data to investigate particular outcomes such as hemorrhagic stroke or all-
cause mortality in isolation. Additionally, lacunar stroke was defined in a 
heterogeneous manner among the trials with only one study using a strict clinical 
criteria and MRI verification of the infarct [3], and we were unable to consider the 
effect specific DAPT regimens in isolation. A final limitation is that our analysis is 
unable to account for possible differences in treatment-effects between the 
acute/semi-acute phase following stroke and the chronic phase. 
 
In conclusion, our results suggest that at present antiplatelet monotherapy of the 
agents included in the trials should be indicated for secondary stroke prevention after 
a lacunar stroke. Furthermore, current data are insufficient to justify using one 
antiplatelet agent over another in this particular population.  
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Figure 1: Risk of outcome with antiplatelet versus placebo 
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Figure 2: Risk of outcome with antiplatelet monotherapy versus aspirin 
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Figure 3: Risk of outcome with dual antiplatelet therapy versus aspirin 
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Figure 4: Risk of outcome with other antiplatelet regimens versus clopidogrel 
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Table 1: Study design and participant characteristics 
Study Midyear 
of study 
Years 
of 
study 
Design; 
country 
No. of 
patients 
with 
lacunar 
stroke(%) 
Intervention Mean 
age  
% 
Male 
Participant 
selection 
Stroke 
ascertainment 
Definition of 
lacunar 
stroke 
specified 
AICLA [8] 1976 Oct 
1975 
to 
Dec 
1978 
Double blind, 
multicenter 
randomized 
trial; four 
centers in 
France. 
98(16%) ASA/ASA+dipyridamole/placebo 63 70% Participants had 
at least one 
cerebral or 
retinal 
atherothromboti
c ischemic event 
whether 
transient or 
complete.  
Neurological 
assessment with 
history and CT 
scan and 
cerebral 
angiography 
was optional. 
No 
CATS [9] Prior to 
1989 
Prior 
to 
1989 
Double blind, 
multicenter 
randomized 
controlled 
trial; 25 
centers in 
Canada. 
274(26%) Ticlopidine/placebo 65 62% Patients with 
thromboembolic 
stroke no less 
than 1 week or 
more than 4 
months before 
entry to the 
study. 
Diagnosis was 
based on a 
neurological 
evaluation and 
assessment of 
clinical course 
and required a 
sudden onset of 
a new 
neurological 
deficit with 
demonstrable 
residual effects 
at time of 
randomization. 
No. 
ESPS-2 
[19] 
1992 Feb 
1989 
to 
Mar 
1995 
Double blind, 
multicenter 
randomized 
controlled 
trial; 16 
centers, 6 
countries. 
2600(59%) ASA/dipyridamole/ASA+dipyridamole/placeb
o 
66 61% Participants with 
minor ischemic 
stroke or TIA. 
Ischemic 
vascular 
accident is 
defined as 
neurological 
deficit due to 
involvement of 
Yes. Small 
vessel 
disease had 
signs and 
symptoms of 
1 of the 
classical 
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the brain or 
brainstem 
without 
symptoms or 
signs of 
hemorrhage or 
tumour. 
 
lacunar 
syndromes 
(pure motor 
stroke, pure 
sensory 
stroke, ataxic 
hemiparesis 
or dysarthria 
clumsy hand 
syndrome). 
IST [11] 1993 Jan 
1991 
to 
May 
1996 
Open 
randomized 
trial; 
international 
467 hospital 
from 36 
countries. 
4616(24%) ASA/control 61% > 
70 
years 
54% Participants with 
acute stroke with 
onset less than 
48 hours 
previously and 
no evidence of 
intracranial 
hemorrhage. 
All patients 
were CT 
scanned and 
eligibility was 
based on view 
of responsible 
physician.  
Classification 
of stroke type 
was based on 
neurological 
deficits. 
No. 
Matsumoto 
2005 [14] 
1994 Apr 
1992 
to 
Mar 
1996 
Double blind 
randomized 
control trial; 
183 institutes 
in Japan. 
794(74%) Cilostazol/placebo 65 66% Participants aged 
<80 years with 
onset of cerebral 
infarction 
between 1 and 6 
months 
confirmed on 
CT or MRI scan 
and no serious 
complications 
were present. 
Diagnosis 
confirmed on 
CT or MRI 
imaging. 
No. 
CAST [10] 1995 Nov 
1993 
to 
Mar 
1997 
Multicenter 
randomized 
controlled 
trial; 413 
hospitals in 
China. 
6263(30%) ASA/placebo 63 64% Participants 
were within 48 
hours of onset of 
symptoms of 
suspected acute 
ischemic stroke 
Patient judged 
to be within 48 
hours of onset 
of symptoms of 
suspected acute 
ischemic stroke 
No. 
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and had no clear 
indication for or 
contraindication
s to aspirin. 
and had CT 
scan. 
Uchiyama 
2009 [23] 
1999 July 
1996 
to 
Nov 
2003 
Double blind, 
multicenter 
randomized 
trial; Japan. 
1341(73%) Clopidogrel/ticlopidine 65 71% Participants had 
recent ischemic 
stroke (Must 
have occurred > 
8 days prior to 
enrolment) 
Brain infarcts 
were 
documented by 
computed 
tomography or 
magnetic 
resonance 
imaging. 
No. 
MATCH 
[13] 
2001 Dec 
2000 
to 
Apr 
2002 
Double blind, 
multicenter 
randomized 
controlled 
trial; 
International 
507 centers in 
28 countries. 
3148(53%) ASA+clopdiogrel/clopidogrel 66 63% Participants had 
ischemic stroke 
or TIA in the 
previous 3 
months with one 
or more of five 
additional risk 
factors within 3 
years. 
Diagnosis and 
stroke type 
according to 
TOAST criteria 
with MRI or CT 
imaging. 
Yes. Small 
vessel 
occlusion 
defined as 
one of the 
traditional 
clinical 
lacunar 
syndromes 
and should 
not have 
evidence of 
cerebral 
cortical  
dysfunction.  
ESPRIT 
[15] 
2001 Jul 
1997 
to 
Dec 
2005 
Multicenter 
randomized 
controlled 
trial; 
International 
79 hospital 
from 14 
countries. 
1377(50%) ASA+dipyridamole/ASA 63 65% Participants had 
TIA within 6 
months or minor 
stroke of arterial 
origin.  
Data collected 
by checklist and 
classification 
was on basis of 
CT or MR scan 
and clinical 
features. 
Small vessel 
disease was 
used as 
lacunar 
stroke but 
not defined. 
S-
ACCESS 
[17] 
2002 Apr 
2001 
to 
Nov 
Double blind, 
multicenter 
randomized 
trial; 113 
963(64%) Sarpogrelate/ASA 65 72% Participants with 
cerebral 
infarction based 
on NINDS 
Symptoms, 
signs and 
evidence on CT 
or MR imaging. 
No. 
 28 
2003 institutes in 
Japan. 
criteria. 
PROFESS 
[16] 
2005 Sept 
2003 
to 
Feb 
2008 
Double blind, 
multicenter 
randomized 
controlled 
trial; 
International, 
695 centers in 
35 countries. 
10578(52%) ASA+dipyridamole/clopidogrel 66 64% Participants had 
recent ischemic 
stroke (within 90 
days of 
randomization) 
with symptoms 
lasting >24 
hours or 
evidence of 
cerebral 
infarction on CT 
or MRI scan, 
clinical and 
neurological 
stability before 
randomization 
and age >55 
years.  Excluded 
were those with 
contraindication 
for antiplatelet 
agents. 
Symptoms of 
ischemic stroke 
with evidence 
of a recent brain 
infarction on 
CT or MRI 
scan. 
No. 
CSPS2 
[18] 
2005 Dec 
2003 
to Oct 
2006 
Double blind, 
multicenter 
randomized 
trial; 278 sites 
in Japan. 
1743(65%) cilostazol/ASA 63 NA Participants with 
non-
cardioembolic 
cerebral 
infarction 
(NINDS-III 
classification) 
with evidence on 
CT or MRI scan 
and age 20-79 
years. 
NINDS-III 
classification 
with evidence 
on CT or MRI 
scan of non-
cardioembolic 
cerebral 
infarction. 
No. 
AAASPS 
[12] 
2006 Dec 
1992 
to Oct 
2001 
Double blind, 
multicenter 
randomized 
trial; 62 
1221(68%) Ticlodipine/ASA 61 53% Participants 
were black race 
of age 29-85 
years of age with 
Cranial 
computed 
tomographic 
scan or 
No. 
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centers in 
USA. 
non-
cardioembolic 
ischemic stroke 
with onset at 
least 7 days but 
not more than 90 
days with 
neurological 
imaging and 
measurable 
neurological 
deficits 
consistent with 
cerebral 
infarction. 
magnetic 
resonance 
imaging of the 
brain consistent 
with cerebral 
infarction. 
SPS3 [3] 2007 2003 
to 
2011 
Double blind, 
multicenter 
randomized 
trial; 
international, 7 
countries. 
3020(100%) ASA+clopidogrel/ASA 63 63% Participants had 
recent lacunar 
stroke. 
Clinical 
diagnosis with 
investigations 
including an 
MRI, ECG, 
ECHO, 
standard blood 
tests and 
imaging of 
cervical and 
intracranial 
arteries. 
Yes. Clinical 
lacunar 
syndrome 
that 
corresponded 
to an 
ischemic 
lesion 
measuring 
2.0 cm or 
less in 
diameter on 
MRI on DWI 
or <1.5 cm 
on 
FLAIR/T1. 
PERFOR
M [21] 
2007 Feb 
2006 
to 
Apr 
2008 
Double blind, 
multicenter 
randomized 
controlled 
trial; 
International 
802 centers in 
46 countries. 
1733(9%) Tetroban/ASA 67 63% Participants 
were aged 55 
years or older, 
who had had an 
ischemic stroke 
or arterial retinal 
ischemic event 
more than 48 
Ischemic stroke 
was confirmed 
by brain 
imaging. 
Yes. 
Ischemic 
stroke was 
categorized 
into lacunar 
stroke based 
on prior 
defined 
 30 
hours and less 
than 3 months 
preceding 
inclusion or a 
TIA in the 
previous 8 days. 
criteria. 
ECLIPSE 
[20] 
2007 Nov 
2006 
to Oct 
2008 
Double blind, 
multicenter 
randomized 
trial; 8 
hospitals in 
Korea. 
203(100%) ASA+cilostazol/ASA 65 75% Participants 
were eligible for 
the trial if they 
experienced 
their first 
lacunar 
infarction within 
the preceding 7 
days and were 
45 years of age 
or older. 
All registered 
patients had a 
brain CT and/or 
MRI to exclude 
hemorrhages 
and other 
causes. 
Yes.  
Lacunar 
infarction 
was 
classified 
according 
the 
Trial of ORG 
10172 in the 
Acute Stroke 
Treatment 
(TOAST) 
classification 
System. 
TRA 2P-
TIMI 50 
[22] 
2009 Sept 
2007 
to 
Dec 
2011 
Double blind, 
multicenter 
randomized 
trial; 
international, 
1032 sites, 32 
countries. 
2262(47%) Vorapaxar/placebo and concomitant 
medications 
65 67% Patients had 
previous 
ischemic stroke 
who were 
hospitalized or 
evaluated in an 
acute stroke 
clinic with a 
final diagnosis 
of ischemic 
stroke within 2 
weeks to 12 
months before 
randomization. 
Ischemic stroke 
based on 
history of 
hospitalization 
with final 
diagnosis of 
nonhemorrhagi
c stroke. 
Yes. Small 
artery 
occlusion 
defined by 
lacunar 
stroke 
generally 
<15 mm 
subcortical 
size 
according to 
TOAST 
criteria. 
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Supplementary Figure I: Flow diagram of study selection 
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Supplementary Table I: Quality of included trials 
Study Sequence generation Allocation concealment Blinding Treatment; exposure; 
ascertainment 
Outcome; outcome 
ascertainment 
Follow up; lost to 
follow up 
AICLA [1] Patients were randomized using a 
established randomization 
schedule, balanced for every 6 
patients. 
Unclear. Double- 
blind. 
330 mg ASA, placebo, 330 mg 
ASA and 75 mg dipyridamole, 
three times a day; exposure for 
duration of study; at each follow 
up patients were asked about drug 
habits and urine salicylate 
measurements were performed. 
Ischemic stroke; 
clinical diagnosis with 
CT scan. 
3 years; 11% 
withdrew from study 
not related to health 
problems, 41% 
discontinued 
treatment, and 8% 
withdrew from study. 
CATS [2] Randomization code used for 
randomization. 
Unclear. Double-
blind. 
500 mg ticlopidine, placebo; 
ascertained by pill counting. 
Any stroke; events 
were classified by 
steering committee. 
2 years; 4 patients 
loss to follow up. 
ESPS-2 [3] Treatment group allocation was 
determined by a randomization 
system based on the minimization 
technique and taking into account 
various factors. 
Unclear. Double-
blind. 
Aspirin 50 mg, modified-release 
dipyridamole 400 mg, aspirin and 
dipyridamole combined and 
placebo; exposure for 2 years; 
unclear ascertainment. 
Any stroke. Unclear 
ascertainment. 
Up to 2 years; unclear 
loss to follow up. 
IST [4] Computer allocated the study 
treatments using a minimization 
algorithm which reduced any 
imbalance in recorded prognostic 
features between treatment groups. 
Adequate allocation concealment 
where patients were allocated by 
telephoning the central 
randomization service at Clinical 
Trial Service Unit, Oxford, UK.  
Not fully 
double- 
blind. 
300 mg ASA or control (avoid 
aspirin); exposure for study 
duration; medication in hospital 
so compliance not an issue. 
Death or dependence; 
outpatient collection of 
data, coordinating 
centre mail a validated 
questionnaire, or 
telephone call 
interview (coordinated 
centrally). 
6 months (0.5 years); 
74 lost at 6 months. 
Matsumoto 
2005 [5] 
Randomization was performed by 
the dynamic balancing method 
adjusted for several variables. 
 
Adequate allocation concealment 
by central Registration and 
Analysis Center, an independent 
organization set up at Tokyo 
University for the present study. 
 
Double-
blind. 
100 mg cilostazol twice daily vs. 
placebo; exposure duration of 
study; unclear ascertainment. 
Ischemic stroke; 
Evaluation Committee 
classified all events. 
2 years (1.8 years in 
cilostazol, 1.6 years in 
placebo); unclear lost 
to follow up. 
CAST [6] Randomization was by prepacked, 
sequentially numbered trial 
envelopes. 
Adequate allocation concealment 
with prepacked sealed envelopes 
produced centrally. 
 
Unclear 
blind. 
160 mg ASA, placebo; exposure 
duration of study; compliance not 
an issue because nurse 
administered medication. 
Death or non-fatal 
stroke; clinical 
diagnosis with CT 
scan. 
4 weeks (0.08 years); 
unclear loss to follow 
up. 
Uchiyama 
2009 [7] 
Unclear. 
 
Unclear. 
 
Double-
blind. 
75 mg clopidogrel or ticlopidine 
200 mg; exposure for 26 weeks or 
Combined ischemic 
stroke, MI and vascular 
26 and 52 weeks; 7 
excluded from 
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52 weeks; unclear ascertainment. death; follow up with 
examination in clinic 
visit or telephone call. 
analysis but 562 
discontinued 
treatment. 
MATCH 
[8] 
Sequence generation  was based on 
a computer-generated list of 
treatment numbers. 
Adequate allocation concealment 
which was done centrally, with an 
interactive voice response system 
(by phone). 
Double-
blind. 
75 mg clopidogrel daily with 75 
mg of aspirin or placebo daily; 
unclear ascertainment. 
Ischemic stroke; 
follow-up visit and 
telephone calls. 
1.5 years; 13 
participants were lost 
to follow up. 
ESPRIT 
[9] 
Treatment allocation was by means 
of computer generated 
randomization codes stratified by 
hospital before the start of the trial.  
Adequate allocation concealment 
with randomization by means of a 
telephone call, fax, or email to the 
central trial office. 
Non-
blinded. 
30-325 mg ASA daily with or 
without 200 mg dipyridamole 
twice daily, exposure for duration 
of study; medication compliance 
asked a follow-up. 
Ischemic stroke and all 
cardiac events (MI, 
sudden death and death 
from cardiac causes); 3 
member committee 
audited outcome events 
and independently 
classified events. 
3.5 years; 106 
participants were lost 
to follow up, 554 
discontinued 
treatment. 
S-
ACCESS 
[10] 
Patients were randomly assigned 
according to an allocation table that 
was generated by using random 
numbers by a person who was not 
part of this study. 
Adequate allocation concealment 
with web-based randomization.  
 
Double-
blind. 
100 mg sarpogrelate three times a 
day vs. 81 mg ASA once daily; 
exposure for duration of study; 
unclear ascertainment. 
Ischemic stroke; 
diagnosis by clinical 
evaluation with 
Efficacy End Point 
Committee. 
1.59 years; 11 not 
included in efficacy 
analysis. 
PROFESS 
[11] 
Unclear. 
 
Adequate allocation concealment 
by a central telephone 
randomization system. 
 
Double-
blind. 
25 mg aspirin and 200 mg 
extended release dipyridamole 
twice daily or 75 mg clopidogrel 
daily; exposure for duration of 
study; compliance was questioned 
at follow up visits. 
Any stroke; ascertained 
by central committee 
using TOAST criteria 
to classify event. 
2.5 years; 0.6% were 
lost to follow up in 
each arm. 
CSPS2 
[12] 
The randomization table was 
generated with SAS and random 
allocation was done with a 
dynamic balancing method to 
minimize differences in the 
distribution of baseline variables 
between the two groups. 
Adequate allocation concealment 
with remote randomization by 
contract research organisation at the 
registration centre. 
 
Double- 
blind. 
100 mg cilostazol twice daily vs. 
81 mg ASA daily; exposure study 
duration, unclear ascertainment. 
Any stroke; 
independent data 
monitoring committee. 
2.42 years; 85 not 
included in analysis, 
793 discontinued drug 
and 4 lost to follow 
up. 
AAASPS 
[13] 
Patients were randomized using a 
algorithm using a length of block 
varying from 2 to 8 with a ratio of 
patients receiving ticlopidine to 
aspirin of 1:1. 
Adequate allocation concealment 
with automated phone registration. 
 
Double-
blind 
650 mg ASA, 500 mg ticlopidine; 
exposure duration of study; 
ascertained by pill counting. 
Any stroke; blinded 
adjudication 
committee. 
1.54 years; 522 
participants withdrew 
from study but all 
were included in 
analysis. 
SPS3 [14] Randomization assignments were Adequate allocation concealment Double- 325 mg ASA daily with or Any stroke, ischemic 3.4 years; no loss to 
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generated using a permuted-block 
design (variable block size). 
using central web-based system.  
 
blind. without 75 mg clopidogrel daily; 
exposure for duration of study; 
adherence measured by pill count. 
stroke, death and MI; 
ascertained by the 
blinded Events 
Adjudication 
Committee.  
follow up. 
PERFOR
M [15] 
The allocation sequence was 
generated by the sponsor through 
in-house application software. The 
randomization was balanced, non-
adaptive, and stratified by country, 
with blocks of size four. 
Adequate allocation concealment 
by a central interactive response 
system (telephone or internet).  
Double-
blind. 
30 mg terutroban daily vs. 100 g 
aspirin daily; unclear 
ascertainment. 
Ischemic stroke, MI, 
vascular death. 
Independent Data 
Monitoring Committee. 
28.3 months; 20 
excluded, 58 lost to 
follow up and 382 
withdrew consent. 
ECLIPSE  
[16] 
A blocked randomization 
procedure generated by a 
statistician was used by the central 
trial pharmacist randomized 
patients. 
Adequate allocation concealment 
with randomization by central trial 
pharmacist who produced identical 
study kits.  
 
Double-
blind. 
100 mg cilostazol BD or placebo 
and ASA 100 mg daily; study 
duration of 90 days; unclear 
ascertainment. 
Any stroke (ischemic 
stroke data also 
provided); follow up 
with transcranial 
doppler and 
examination. 
90 days;  no lost to 
follow up. 
TRA 2P-
TIMI 50 
[17] 
Unclear. Adequate allocation concealment 
by a central computerized telephone 
system. 
 
Double-
blind. 
2.5 mg vorapaxar daily vs. 
placebo added to standard 
antiplatelet therapy; unclear 
ascertainment. 
Cardiovascular death, 
MI or stroke; 
ascertained by a 
Clinical Events 
Committee blinded to 
treatment allocation. 
Median 24 months 
(up to 3 years). 32 lost 
to follow up and 532 
withdrew consent for 
follow up. 
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Supplementary Table II: Treatments, outcomes, crude events and follow up of studies included 
Study Midyear 
of study 
Treatment 
experimental/contr
ol 
Outcome  Experi
mental 
events 
Total Adjusted to 
time 
(outcome/yr) 
Control 
events 
Total Adjusted to 
time 
(outcome/yr) 
Trial follow-up 
duration (mean) 
Reported HRs 
(95% CI) for 
outcome 
AICLA [1] 1976 ASA/placebo Ischemic stroke 3 30 3.33% 9 34 8.82% 3 years   - 
1976 ASA+dipyridamole/
ASA 
Ischemic stroke 2 34 1.96% 3 30 3.33% 3 years  - 
CATS [2] Prior to 
1989 
Ticlopidine/placebo Any stroke 14 137 5% 27 137 10% 2 years   
ESPS-2 [3] 1992 ASA/placebo Any stroke 70 609 6.4% 93 681 7.9% 1.7-1.8 years 0.82 (0.60-1.11) 
1992 Dipyridamole/place
bo 
Any stroke 73 651 6.3% 93 681 7.9% 1.7 years  0.80 (0.59-1.08) 
1992 ASA+dipyridamole/
placebo 
Any stroke 52 659 4.4% 93 681 7.9% 1.7-1.8 years 0.56 (0.40-0.78) 
1992 ASA+dipyridamole/
ASA 
Any stroke 52 659 4.4% 70 609 6.4% 1.8 years 0.68 (0.48-0.97) 
1992 ASA/placebo Composite 
vascular events* 
101 609 9.4% 128 681 11.0% 1.7-1.8 years 0.86 (0.66-1.11) 
1992 Dipyridamole/place
bo 
Composite 
vascular events* 
108 651 9.5% 128 681 11.0% 1.7 years  0.86 (0.67-1.12) 
1992 ASA+dipyridamole/
placebo 
Composite 
vascular events* 
82 659 7.0% 128 681 11.0% 1.7-1.8 years 0.64 (0.48 – 0.84) 
1992 ASA+dipyridamole/
ASA 
Composite 
vascular events* 
82 659 7.0% 101 609 9.4% 1.8 years 0.74 (0.55-0.99) 
IST [4] 1993 ASA/control Death or 
dependence 
1112 2308 - 1116 2308 - 6 months = 0.5 
years 
- 
Matsumoto 
2005 [5] 
1994 Cilostazol/placebo Ischemic stroke 20 400 2.97% 39 394 5.25% 2 years (1.8 years 
in cilostazol, 1.6 
years in placebo) 
- 
CAST [6] 1995 ASA/placebo Any (non-fatal) 
stroke or death 
78 3117 -  88 3146 - 4 weeks = 0.08 
years 
  
Uchiyama 
2009 [7] 
1999 Clopidogrel/ticlopid
ine 
Ischemic stroke, 
MI, vascular 
death 
19 677 2.8% 22 664 3.3% Up to 1 year.  
MATCH [8] 2001 ASA+clopdiogrel/cl
opidogrel 
Ischemic stroke 160 1590 7.70% 161 1558 8.10% 18 months = 1.5 
years 
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ESPRIT [9] 2001 ASA+dipyridamole/
ASA 
Ischemic stroke 
and all cardiac 
events (MI, 
sudden death 
and death from 
cardiac causes) 
96 687 3.99% 106 690 4.39% 3.5 years   
S-ACCESS 
[10] 
2002 Sarpogrelate/ASA Ischemic stroke 46 484 5.95% 35 479 4.53% 1.59 years HR 1.31 (0.84-
2.04) 
PROFESS 
[11] 
2005 ASA+dipyridamole/
clopidogrel 
Any stroke 418 5292 3.16% 437 5286 3.31% 2.5 years   
CSPS2 [12] 2005 cilostazol/ASA Any stroke 59 869 3.06% 85 874 4.07% 2.42 years HR 0.752 (0.542-
1.042) 
AAASPS 
[13] 
2006 Ticlodipine/ASA Any stroke 55 600 6% 48 621 5% 1.54 years   
SPS-3 [14] 2007 ASA+clopidogrel/A
SA 
Ischemic stroke 100 1517 2.00% 124 1503 2.40% 3.4 years   0.82 (0.63-1.09) 
2007 ASA+clopidogrel/A
SA 
Any stroke 125 1517 2.50% 138 1503 2.70% 3.4 years  0.92 (0.72-1.16) 
2007 ASA+clopidogrel/A
SA 
Any stroke, MI, 
death. 
269 1517 - 253 1503 - 3.4 years - 
PERFORM 
[15] 
2007 Tetroban/ASA. Ischemic stroke, 
MI and vascular 
death. 
54 856 2.55% 61 877 2.98%% 28.3 months = 2.35 
years 
0.90 (0.62-1.13) 
ECLIPSE 
[16] 
2007 ASA+cilostazol/AS
A 
Any stroke (all 
events 
ischemic) 
1 100 - 1 103 - 0.25 years - 
TRA 2P-
TIMI 50 
[17] 
2009 Vorapaxar/placebo 
and concomitant 
medications 
Any stroke, MI, 
cardiovascular 
death. 
- 2262 
(total) 
3.80% - 2262 
(total) 
3.77 % 3 years 0.99 (0.75-1.31) 
 
*Composite vascular events defined as nonfatal stroke, nonfatal MI, a nonfatal vascular events (DVT, PE, peripheral artery occlusion, venous retinal vascular event) or vascular death. 
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Supplementary Data I: Search Strategy 
 
Database: Embase <1974 to 2013 Week 50>, Ovid MEDLINE(R) In-Process & Other Non-
Indexed Citations and Ovid MEDLINE(R) <1946 to Present> 
Search Strategy: 
-------------------------------------------------------------------------------- 
1     Aspirin or Clopidogrel or Ticlopidine or Dipyridamole or Prasugrel or Ticagrelor or 
Cilostazol or Dipyridamole {No Related Terms} (6084) 
2     Platelet aggregation inhibitors or Antiplatelet {No Related Terms} (69182) 
3     Platelet Aggregation Inhibitors {No Related Terms} (5716) 
4     Stroke or cerebrovascular disease or cerebrovascular accident {No Related Terms} 
(8654) 
5     Stroke/ (186298) 
6     Brain Ischemia/ (112183) 
7     Cerebrovascular Disorders/ (91210) 
8     randomised controlled trial or randomized controlled trial or randomised controlled study 
or randomized controlled study {No Related Terms} (9836) 
9     Randomized Controlled Trial/ (755711) 
10     1 or 2 or 3 (77570) 
11     4 or 5 or 6 or 7 (355197) 
12     8 or 9 (755716) 
13     10 and 11 and 12 (536) 
14     remove duplicates from 13 (431) 
 
*************************** 
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